New pill aims to slow lung scarring in fibrosis patients
NCT ID NCT07284459
First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 24 times
Summary
This study tests an experimental oral drug called PIPE-791 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. About 324 adults aged 40 and older will receive either the drug or a placebo to see if it improves lung function and is safe. Participants may continue their usual IPF medications during the trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr. Anil Dhar Medicine Professional Corporation
RECRUITINGWindsor, Ontario, N8X 5A6, Canada
-
Dynamic Drug Advancement Ltd.
RECRUITINGAjax, Ontario, L1S 2J5, Canada
Conditions
Explore the condition pages connected to this study.